Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565434 | 1.00 | KDM4E (0.39) | KDM4EMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL27141821 | 0.82 | ATR (0.42) | MEN1KMT2A | |
| SCHEMBL29565827 | 0.79 | KDM4E (0.38) | KDM4EMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL16856891 | 0.79 | KDM4E (0.38) | KDM4EMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL18383188 | 0.76 | ALDH1A1 (0.43) | KDM4EMEN1KMT2ARAB9AMITF | |
| SCHEMBL2587336 | 0.73 | S1PR2 (0.62) | KDM4EMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL31748884 | 0.72 | RAB9A (0.43) | KDM4EMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25137117 | 0.71 | ATR (0.40) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL25136736 | 0.71 | ATR (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL8365771 | 0.70 | L3MBTL1 (0.42) | KDM4ERAB9AALDH1A1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358931-B2 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240132520-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-04-25 | — | — | US | disclosed |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-111362975-B | Naphthyridine compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20210179637-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10947254-B2 | Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| CN-111362975-A | Naphthyridine compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-107667108-B | Naphthyridine compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-05-12 | — | — | CN | disclosed |
| US-20200040010-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3569604-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3303348-B1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180354974-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-12-13 | — | — | US | disclosed |
| US-10072026-B2 | Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| EP-3303348-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170305934-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-26 | — | — | US | disclosed |
| US-9725470-B2 | Substituted naphthyridines as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160347772-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016191524-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358931-B2 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | JAK1, JAK3, JAK2 | KDM4E 272/4885MEN1 3061/4885KMT2A 1114/4885 |
| US-20160347772-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 804/4885MEN1 2930/4885KMT2A 1076/4885 |
| US-11780852-B2 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | ALPI, TPMT, SLC10A2 | KDM4E 610/4885MEN1 2907/4885KMT2A 2936/4885 |
| US-10947254-B2 | Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | ALPI, TPMT, SI | KDM4E 677/4885MEN1 4381/4885KMT2A 3531/4885 |
| US-20180354974-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 804/4885MEN1 2930/4885KMT2A 1076/4885 |
| US-20170305934-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 804/4885MEN1 2930/4885KMT2A 1076/4885 |
| US-10072026-B2 | Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | JAK1, JAK3, MAP3K1 | KDM4E 414/4885MEN1 3369/4885KMT2A 2380/4885 |
| US-20210179637-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 804/4885MEN1 2930/4885KMT2A 1076/4885 |
| US-20240132520-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 804/4885MEN1 2930/4885KMT2A 1076/4885 |
| US-20200040010-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK2, JAK3 | KDM4E 804/4885MEN1 2930/4885KMT2A 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.